NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Invesco Ltd.

Invesco Ltd. lowered its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 6.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 410,967 shares of the medical research company's stock after selling 27,789 shares during the period. Invesco Ltd. owned 0.32% of NeoGenomics worth $6,773,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in NeoGenomics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock worth $234,673,000 after acquiring an additional 195,793 shares during the last quarter. Segall Bryant & Hamill LLC increased its stake in NeoGenomics by 11.6% in the 4th quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company's stock valued at $34,836,000 after buying an additional 220,415 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of NeoGenomics by 2.0% during the 3rd quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company's stock worth $28,225,000 after buying an additional 39,740 shares in the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of NeoGenomics by 48.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,791,792 shares of the medical research company's stock valued at $29,528,000 after acquiring an additional 584,502 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of NeoGenomics by 18.7% during the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock valued at $24,963,000 after acquiring an additional 238,288 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.

NeoGenomics Stock Performance

Shares of NEO stock traded down $0.30 during trading hours on Monday, reaching $9.97. The company had a trading volume of 1,602,026 shares, compared to its average volume of 969,441. The firm has a market cap of $1.28 billion, a PE ratio of -16.08 and a beta of 1.41. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The business has a fifty day moving average price of $9.80 and a 200-day moving average price of $13.48. NeoGenomics, Inc. has a one year low of $8.05 and a one year high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million during the quarter, compared to analysts' expectations of $173.40 million. Sell-side analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NEO has been the subject of several research analyst reports. The Goldman Sachs Group decreased their target price on NeoGenomics from $17.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Needham & Company LLC dropped their price objective on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Piper Sandler reduced their target price on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Bank of America cut their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. Finally, Benchmark lowered shares of NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $19.30.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.